Elisa F. Long, PhD; Margaret L. Brandeau, PhD; Douglas K. Owens, MD, MS
Long EF, Brandeau ML, Owens DK. The Cost-Effectiveness and Population Outcomes of Expanded HIV Screening and Antiretroviral Treatment in the United States. Ann Intern Med. 2010;153:778-789. doi: 10.7326/0003-4819-153-12-201012210-00004
Download citation file:
Published: Ann Intern Med. 2010;153(12):778-789.
Although recent guidelines call for expanded routine screening for HIV, resources for antiretroviral therapy (ART) are limited, and all eligible persons are not currently receiving treatment.
To evaluate the effects on the U.S. HIV epidemic of expanded ART, HIV screening, or interventions to reduce risk behavior.
Dynamic mathematical model of HIV transmission and disease progression and cost-effectiveness analysis.
High-risk (injection drug users and men who have sex with men) and low-risk persons aged 15 to 64 years in the United States.
Twenty years and lifetime (costs and quality-adjusted life-years [QALYs]).
Expanded HIV screening and counseling, treatment with ART, or both.
New HIV infections, discounted costs and QALYs, and incremental cost-effectiveness ratios.
One-time HIV screening of low-risk persons coupled with annual screening of high-risk persons could prevent 6.7% of a projected 1.23 million new infections and cost $22 382 per QALY gained, assuming a 20% reduction in sexual activity after screening. Expanding ART utilization to 75% of eligible persons prevents 10.3% of infections and costs $20 300 per QALY gained. A combination strategy prevents 17.3% of infections and costs $21 580 per QALY gained.
With no reduction in sexual activity, expanded screening prevents 3.7% of infections. Earlier ART initiation when a CD4 count is greater than 0.350 × 109 cells/L prevents 20% to 28% of infections. Additional efforts to halve high-risk behavior could reduce infections by 65%.
The model of disease progression and treatment was simplified, and acute HIV screening was excluded.
Expanding HIV screening and treatment simultaneously offers the greatest health benefit and is cost-effective. However, even substantial expansion of HIV screening and treatment programs is not sufficient to markedly reduce the U.S. HIV epidemic without substantial reductions in risk behavior.
National Institute on Drug Abuse, National Institutes of Health, and Department of Veterans Affairs.
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, HIV, High Value Care.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only